B. Riley Has Pessimistic Outlook of LifeMD Q3 Earnings

Key Points

• B. Riley has revised its earnings estimates for LifeMD, projecting a Q3 2025 loss of ($0.05) per share, worse than their prior estimate of ($0.04).
• Several analysts have recently adjusted their price targets for LifeMD, with reductions from $18.00 to $14.00 and from $14.00 to $12.00, indicating a mixed outlook on the stock.
• Insider trading activity has increased, with notable sales including CFO Marc David Benathen offloading 75,000 shares for approximately $981,750.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Stock analysts at B. Riley decreased their Q3 2025 earnings estimates for shares of LifeMD in a research report issued to clients and investors on Wednesday, August 6th. B. Riley analyst A. Schock now forecasts that the company will earn ($0.05) per share for the quarter, down from their previous estimate of ($0.04). The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. B. Riley also issued estimates for LifeMD's Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.09 EPS and FY2026 earnings at $0.27 EPS.

Several other research analysts have also commented on LFMD. KeyCorp lowered their price objective on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research note on Wednesday, August 6th. HC Wainwright dropped their target price on shares of LifeMD from $14.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Wall Street Zen cut shares of LifeMD from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. BTIG Research increased their target price on shares of LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, June 18th. Finally, Lake Street Capital dropped their price objective on LifeMD from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, LifeMD presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.86.

LifeMD Trading Down 0.5%

NASDAQ LFMD traded down $0.04 during trading hours on Monday, reaching $6.80. The company had a trading volume of 1,565,989 shares, compared to its average volume of 1,670,652. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. The stock has a market capitalization of $322.22 million, a P/E ratio of -32.41 and a beta of 1.72. The stock has a 50-day moving average of $11.63 and a 200 day moving average of $8.52. LifeMD has a 1-year low of $3.99 and a 1-year high of $15.84.

Insider Buying and Selling

In related news, insider Eric Harold Yecies sold 15,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $12.25, for a total value of $183,750.00. Following the completion of the sale, the insider directly owned 16,100 shares in the company, valued at approximately $197,225. This represents a 48.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Marc David Benathen sold 75,000 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $13.09, for a total transaction of $981,750.00. Following the completion of the transaction, the chief financial officer owned 389,554 shares in the company, valued at $5,099,261.86. The trade was a 16.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 275,000 shares of company stock valued at $3,564,550. Insiders own 18.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of LifeMD during the fourth quarter worth approximately $56,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in LifeMD by 17.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,412 shares of the company's stock worth $235,000 after buying an additional 7,001 shares in the last quarter. Northern Trust Corp grew its holdings in LifeMD by 2.1% during the 4th quarter. Northern Trust Corp now owns 323,974 shares of the company's stock worth $1,604,000 after acquiring an additional 6,634 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after acquiring an additional 2,895 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in LifeMD in the 4th quarter valued at about $279,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.